Cargando…

Intravitreal Vascular Endothelial Growth Factor Inhibitor Use and Renal Function Decline in Patients with Diabetic Retinopathy

Adverse renal effects of systemic vascular endothelial growth factor (VEGF) inhibitor treatment are well documented. We aimed to identify associations between intravitreal VEGF inhibitor use and renal function decline in patients with diabetic retinopathy. We included 625 patients with diabetic reti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Shih-Hsiang, Yin, Chun-Hao, Chung, Tung-Ling, Chen, Hsin-Yu, Chen, Chien-Liang, Chen, Jin-Shuen, Lee, Po-Tsang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657653/ https://www.ncbi.nlm.nih.gov/pubmed/36361175 http://dx.doi.org/10.3390/ijerph192114298

Ejemplares similares

Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy
por: Ou, Shih-Hsiang, et al.
Publicado: (2020)

Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy
por: Shye, Michael, et al.
Publicado: (2020)

Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
por: Chung, Eun Jee, et al.
Publicado: (2011)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment
por: Chang, Yu-Shan, et al.
Publicado: (2019)

Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity
por: Mirghorbani, Masoud, et al.
Publicado: (2022)

Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
por: Fernando Arevalo, J.
Publicado: (2013)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
por: Chatziralli, Irini, et al.
Publicado: (2021)

Secretome of Hypoxic Endothelial Cells Stimulates Bone Marrow-Derived Mesenchymal Stem Cells to Enhance Alternative Activation of Macrophages
por: Chou, Kang-Ju, et al.
Publicado: (2020)

Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity
por: Chen, Jing, et al.
Publicado: (2023)

Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
por: Taher, Nada O., et al.
Publicado: (2022)

Effect of pan-retinal laser photocoagulation on intravitreal vascular endothelial growth factor concentration in proliferative diabetic retinopathy
por: Nišić, Faruk, et al.
Publicado: (2022)

Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach
por: Petri, Anne-Sofie, et al.
Publicado: (2020)

Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study
por: Huang, Yu‐Shan, et al.
Publicado: (2022)

Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease
por: Kameda, Yusuke, et al.
Publicado: (2018)

Safety and efficacy of intravitreal anti vascular endothelial growth factor for severe posterior retinopathy of prematurity with flat fibrovascular proliferation
por: Maitra, Puja, et al.
Publicado: (2023)

Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature
por: Palakkamanil, Mathew, et al.
Publicado: (2023)

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy
por: Kianersi, Farzan, et al.
Publicado: (2021)

Intravitreal Vascular Endothelial Growth Factor Inhibitor Therapy in Denmark and 5-Year Projections
por: Thinggaard, Benjamin Sommer, et al.
Publicado: (2023)

Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy
por: Li, Bing, et al.
Publicado: (2020)

Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity
por: Vinekar, Anand
Publicado: (2021)

Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2–induced intravitreal neovascularization in a rat model of retinopathy of prematurity
por: Wang, Haibo, et al.
Publicado: (2014)

Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study
por: Ou, Shih-Hsiang, et al.
Publicado: (2021)

Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion
por: Hwang, De-Kuang, et al.
Publicado: (2020)

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
por: Campbell, Robert J, et al.
Publicado: (2012)

Pituitary Apoplexy After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A Novel Complication
por: Kasl, Rebecca A., et al.
Publicado: (2015)

Nephrotic Syndrome with Focal Segmental Glomerulosclerosis Induced by Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitor
por: Kakeshita, Kota, et al.
Publicado: (2020)

Association between Obstetric Complications and Intravitreal Anti-Vascular Endothelial Growth Factor Agents or Intravitreal Corticosteroids
por: Ben Ghezala, Inès, et al.
Publicado: (2022)

Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study
por: Jiang, Lin, et al.
Publicado: (2023)

Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
por: Bordin, Fernando Longhi, et al.
Publicado: (2023)

Diabetic retinopathy and vascular endothelial growth factor
por: Khazaei, Majid
Publicado: (2013)

Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity
por: Kang, Hyun Goo, et al.
Publicado: (2019)

Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
por: Zhang, Haitao, et al.
Publicado: (2022)

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
por: Hang, Abraham, et al.
Publicado: (2023)

Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension
por: Hanna, Ramy M, et al.
Publicado: (2018)

Increased Circulating Endothelial Apoptotic Microparticle to Endothelial Progenitor Cell Ratio Is Associated with Subsequent Decline in Glomerular Filtration Rate in Hypertensive Patients
por: Hsu, Chien-Yi, et al.
Publicado: (2013)

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
por: Lin, Tai-Chi, et al.
Publicado: (2021)

Deficiency of Urokinase Plasminogen Activator May Impair β Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus
por: Wu, Chung-Ze, et al.
Publicado: (2019)

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hc2pp5a0veke738cl7qfue3gem